PubMed Triage Digest — 2026-06-28
Run: Attempt 2 · 2026-06-28T18:06:35Z
Date window: 2026-06-27 → 2026-06-28 (CRDT)
Candidates reviewed: 114 across 9 topics
Selected: 27 articles (10 HIGH · 17 STANDARD)
🔴 HIGH-Priority Articles (Score ≥ 8)
1. CBC + ML for EBV-HLH vs IM Triage in Children — Score 10
PMID: 42365248
Journal: BMC Infectious Diseases · Jun 27, 2026
Topic: CBC/ML Hematology
Authors: Xiao L, Liao M et al. (Children's Hospital Chongqing Medical University)
Random Forest model using routine CBC parameters (WBC, PLT, LAC, Hb) collected within 24h of admission distinguishes EBV-associated hemophagocytic lymphohistiocytosis (HLH) from the far more common and self-limiting infectious mononucleosis in 4,871 pediatric patients across two campuses. AUC 0.993 (internal) and 0.971 (external validation). SHAP analysis confirmed WBC, platelet count, lactic acid, and hemoglobin as top predictors. A free online Shiny decision-support tool is provided.
Key finding: Routine CBC-based RF model achieves near-perfect discrimination of life-threatening EBV-HLH from EBV-IM, enabling cost-effective admission-level triage in diverse healthcare settings.
2. Epigenetic Clock Rate Change Predicts Brain Atrophy and Dementia — Score 9
PMID: 42363718
Journal: Alzheimer's & Dementia · Jul 2026
Topic: Aging & Longevity
Authors: Gebremedhin Asefa N, Romero JM, Launer L et al. (NIA/NIH; Icelandic Heart Association)
AGES-Reykjavik Study (n=2,081) with midlife and late-life assessments shows that shifting to accelerated DunedinPACE biological aging during adulthood independently predicts lower brain volumes and incident dementia. Associations with brain infarcts and cognitive function mainly reflected cumulative cardiovascular risk exposures across the life course rather than late-life aging acceleration per se.
Key finding: Dynamic change in epigenetic pace-of-aging clock is a tractable blood-based predictor of brain structural damage and dementia, separate from static cardiovascular risk factors.
3. GLP-1 RA and SGLT2i Cardiovascular Efficacy — Network Meta-Analysis of 133 RCTs — Score 9
PMID: 42365335
Journal: Diabetology & Metabolic Syndrome · Jun 27, 2026
Topic: Cardiovascular-Metabolic
Authors: Mohammadi D, Sadeghirad B, Moradi Y et al. (Kurdistan University Medical Sciences)
Largest NMA comparing all antidiabetic drug classes across CV endpoints: 133 RCTs, 289,558 participants. GLP-1 receptor agonists reduce cardiovascular mortality (RR=0.85, 95%CI 0.75–0.98; high-certainty) and stroke (RR=0.83; high-certainty). SGLT2 inhibitors most strongly reduce heart failure (RR=0.64; high-certainty) and CV hospitalization (RR=0.72). DPP-4 inhibitors showed indirect suggestion of lower CV mortality versus GLP-1 RAs but with network imbalance caveat.
Key finding: High-certainty evidence establishes GLP-1 RAs as preferred for stroke/CV-mortality and SGLT2i as preferred for heart failure prevention; provides definitive prescribing hierarchy for cardiometabolic risk management.
4. Vibecotamab Phase II in AML-MRD, MDS/CMML After HMA Failure — Score 9
PMID: 42365365
Journal: Journal of Hematology & Oncology · Jun 27, 2026
Topic: Hematologic Malignancies
Authors: Short NJ, Bataller A, DiNardo CD, Ravandi F et al. (MD Anderson Cancer Center)
Phase II study of vibecotamab (CD123/CD3 bispecific antibody) in 48 patients with AML-MRD or MDS/CMML after hypomethylating agent failure. AML-MRD cohort: 19% MRD clearance rate by flow cytometry. MDS/CMML cohort: 67% ORR (18/27). Median OS 13.1 months (AML-MRD) and 6.5 months (MDS/CMML). CRS occurred in 60% but was predominantly grade 1–2.
Key finding: CD123/CD3 bispecific vibecotamab shows meaningful activity in low-blast myeloid diseases with high unmet need; CD123-targeting bispecifics warrant further development alone or in combination.
5. Sotatercept for HFpEF-Associated Pulmonary Hypertension — Phase 2 CADENCE — Score 8
PMID: 42365223
Journal: Heart Failure Reviews · Jun 28, 2026
Topic: Cardiovascular-Metabolic
Authors: Sperry BW, Carlino I, Palazzuoli A
Mini-review of Phase 2 CADENCE trial: sotatercept (activin signaling inhibitor targeting vascular remodeling) met its primary endpoint by reducing PVR at 24 weeks in HFpEF-associated combined pre/post-capillary pulmonary hypertension (CpcPH). Also improved mPAP, wedge pressure, 6MWD, NYHA class, and NT-proBNP without the compensatory LV pressure rise seen with vasodilators. Lower 0.3 mg/kg dose outperformed 0.7 mg/kg on multiple hemodynamic endpoints.
Key finding: Sotatercept is the first non-vasodilatory, potentially disease-modifying option for CpcPH-HFpEF; Phase 3 trial warranted to confirm durable clinical benefit.
6. IMMPACT-MM: Early-Line Cilta-cel in Multiple Myeloma — Score 8
PMID: 42365547
Journal: Oncology and Therapy · Jun 28, 2026
Topic: Hematologic Malignancies · Novel Therapeutics
Authors: Rajeeve S, Nagar SP, Anderson LD Jr et al.
Real-world analysis characterizing outcomes of MM patients receiving early-line cilta-cel (BCMA-targeted CAR-T), exploring patient and disease factors associated with durable responses and adverse events in settings beyond the approved late-line relapsed/refractory indication.
Key finding: Early-line cilta-cel achieves real-world outcomes, with response depth and durability characterized by disease burden and prior treatment profile, supporting ongoing trials of frontline CAR-T strategies in MM.
7. Inotuzumab Ozogamicin for MRD in Adult ALL — Score 8
PMID: 42365008
Journal: Blood Cancer Journal · Jun 27, 2026
Topic: Hematologic Malignancies · Novel Therapeutics
Authors: Jabbour E, Rausch CR, Kantarjian H et al. (MD Anderson Cancer Center)
Clinical study of inotuzumab ozogamicin (CD22-targeted ADC) for MRD clearance in adult ALL with persistent measurable residual disease. Provides evidence for MRD-directed use of an already-approved agent, potentially expanding its clinical application to pre-emptive MRD eradication before disease relapse.
Key finding: Inotuzumab ozogamicin achieves meaningful MRD clearance in adult ALL, supporting its use as a MRD-directed strategy to improve transplant eligibility and prevent overt relapse.
8. Brexu-cel + Consolidative Allo-HCT in B-ALL: ROCCA Real-World Data — Score 8
PMID: 42364734
Journal: Transplantation and Cellular Therapy · Jun 27, 2026
Topic: Hematologic Malignancies · Novel Therapeutics
Authors: Faramand RG, Muffly LS et al. (41 US institutions — ROCCA consortium)
Retrospective multi-center analysis (n=65, 41 US institutions) of adults with R/R B-ALL undergoing consolidative allo-HCT after brexu-cel CAR-T remission. 1-year post-HCT OS 79% (95%CI 64–88%), EFS 66% (95%CI 51–77%), relapse 19%, NRM 13%. Acute grade II–IV GVHD 18%; grade III–IV 4%. Age ≥40 associated with inferior OS (HR 4.31) and myeloablative conditioning with improved EFS.
Key finding: Consolidative allo-HCT after brexu-cel CAR-T is feasible with encouraging survival and low relapse rates; prospective studies are needed to optimize patient selection and conditioning regimens.
9. Asciminib Resistance Landscape in BCR::ABL1 — Dual Functional Genomics — Score 8
PMID: 42365381
Journal: Genome Medicine · Jun 27, 2026
Topic: Hematologic Malignancies · Precision Oncology
Authors: Sokirniy I, Yang Z, Pritchard J
Dual functional genomics screen maps the full landscape of asciminib (STAMP inhibitor) resistance mutations in BCR::ABL1, revealing broad convergence across novel kinase domain variants beyond the canonical myristate binding pocket. Provides mechanistic basis for sequential therapy and next-generation allosteric inhibitor design in CML.
Key finding: Asciminib resistance involves convergent BCR::ABL1 mutations broadly distributed across the kinase domain, challenging assumptions about STAMP-site exclusivity and informing next-generation CML salvage strategies.
10. PD-L1 TPS Intrinsically Limited for Neoadjuvant NSCLC — 30-Pathologist International Study — Score 8
PMID: 42364306
Journal: Lung Cancer · Jun 26, 2026
Topic: Novel Therapeutics · Precision Oncology
Authors: Steinestel K, Löwer-Kiem LM, Elsner F et al. (29 pathologists, 11 countries)
30 pathologists from 11 countries independently scored PD-L1 TPS in 30 digitized NSCLC cases. Interobserver agreement improved from moderate (ICC 0.74) to near-perfect (ICC 0.99) when scores were averaged, yet TPS–residual viable tumor correlation remained absent (r=−0.16, p=0.39) regardless of rater aggregation. Confirmed this is an intrinsic biomarker limitation, not a pathologist variability issue.
Key finding: PD-L1 TPS fails to predict pathological response in neoadjuvant NSCLC regardless of observer agreement, definitively establishing the need for alternative predictive biomarkers beyond PD-L1 in this growing indication.
🟡 STANDARD Articles (Score 5–7)
| PMID | Score | Title (short) | Journal | Topic |
|---|---|---|---|---|
| 42364327 | 7 | CTC + PD-L1 CPS dynamic monitoring in stage III gastric cancer | Int Immunopharmacol | Novel Therapeutics |
| 42364974 | 7 | CD52 drives PDAC metastasis and immunosuppression (scRNA-seq) | Oncogenesis | Novel Therapeutics |
| 42365243 | 7 | Tamibarotene + ATRA in non-APL AML; LSD1/GCN5 inhibition synergy | BMC Cancer | Hematologic Malignancies |
| 42364971 | 7 | QSP model of BCMA/GPRC5D CAR-T response determinants in MM | Clin Pharmacol Ther | Hematologic Malignancies |
| 42365196 | 7 | FGFR3 and ERBB2 complementary distribution in metastatic urothelial carcinoma | Int J Clin Oncol | Precision Oncology |
| 42365267 | 7 | Interpretable ML (CatBoost) for prolonged ICU LOS after CABG; MIMIC-IV + eICU external validation | BMC Med Inform Decis Mak | AI/ML Diagnostics |
| 42364580 | 7 | Multi-stage microfluidic chip for CTC capture + SERS phenotyping in prostate cancer | Biosens Bioelectron | Early Cancer Detection |
| 42364742 | 6 | Time-dependent diffusion MRI differentiates PCNSL from GBM | Magn Reson Imaging | AI/ML Diagnostics |
| 42363763 | 6 | Large mtDNA rearrangements persist in prematurely aging POLG exo− mice | Nucleic Acids Res | Aging & Longevity |
| 42364830 | 6 | Wearable digital biomarkers predict chemotherapy toxicity and survival in oncology | Crit Rev Oncol Hematol | AI/ML Diagnostics |
| 42365316 | 6 | IFN-β hijacks MEK signaling to drive dormancy in colorectal cancer | J Exp Clin Cancer Res | Novel Therapeutics |
| 42365113 | 6 | Flu/Cy/2Gy TBI + PT-Cy single platform for haplo/MUD allo-SCT in older AML/MDS | Bone Marrow Transplant | Hematologic Malignancies |
| 42365009 | 6 | ctDNA dPCR vs NGS for longitudinal MRD monitoring in Hodgkin lymphoma | Blood Cancer J | Hematologic Malignancies |
| 42365079 | 6 | Patient-derived organoids predict drug sensitivity in bladder cancer | Sci Rep | Precision Oncology |
| 42365517 | 5 | MDS with very poor-risk cytogenetics subgroup: relatively favorable allo-HCT outcomes | Am J Hematol | Hematologic Malignancies |
| 42364731 | 5 | Liver autoantibodies in Wilson disease: increased prevalence, unclear significance | Adv Med Sci | Rare Diseases |
| 42365384 | 5 | Biology-aligned cervical cancer screening: next-gen biomarker frameworks | Biomark Res | Early Cancer Detection |
Topic Coverage Summary
| Topic | Candidates | HIGH | STANDARD | Notes |
|---|---|---|---|---|
| Hematologic Malignancies | 20 | 5 | 5 | Vibecotamab Phase II, Cilta-cel early-line, InO-MRD, Brexu+allo-HCT, Asciminib resistance |
| CBC/ML Hematology | 1 | 1 | 0 | Single candidate; top score this round |
| Early Cancer Detection | 9 | 0 | 3 | No liquid biopsy breakthrough today; CTC microfluidics best |
| AI/ML Diagnostics | 20 | 0 | 3 | Post-CABG ICU LOS ML + PCNSL MRI + wearables |
| Precision Oncology | 7 | 0 | 3 | FGFR3/ERBB2 urothelial, PDO bladder, PDAC CD52 |
| Novel Therapeutics | 20 | 1 | 4 | PD-L1 TPS NSCLC HIGH; CTC gastric, PDAC, dormancy, wearables |
| Cardiovascular-Metabolic | 20 | 2 | 1 | GLP-1/SGLT2 NMA + sotatercept PH both HIGH |
| Aging & Longevity | 12 | 1 | 1 | DunedinPACE aging clock predicts dementia HIGH |
| Rare Diseases | 5 | 0 | 1 | Wilson disease autoantibodies only |
Notable Signals
- Bispecific antibodies cementing role in hematology: vibecotamab (CD123/CD3) in AML/MDS, plus QSP modeling of BCMA/GPRC5D CAR-T determinants; pattern of expanding indications beyond approved settings.
- CBC as a workhorse AI input: EBV-HLH model (score 10) reinforces that routine blood counts, when combined with machine learning, unlock high-stakes clinical decisions at near-zero marginal cost.
- CAR-T consolidation with allo-HCT: ROCCA data clarifies the role of transplant after brexu-cel in B-ALL; age ≥40 is an emerging risk stratifier.
- GLP-1 RA vs SGLT2i hierarchy now high-certainty: 133-RCT NMA formally establishes endpoint-specific class superiority — actionable for prescribers managing cardiometabolic risk.
- PD-L1 TPS is definitively inadequate as a neoadjuvant NSCLC predictor regardless of pathologist agreement — opens space for better biomarker candidates (TMB, ctDNA, RNA signatures).
- Sotatercept breaks the vasodilator-only paradigm for HFpEF-PH; Phase 3 design is the next watchpoint.
- Epigenetic clocks beyond static measurement: AGES-RS study shows rate of change in DunedinPACE outperforms baseline level for brain outcome prediction.
Generated by PubMed Triage Agent · Attempt 2 · 2026-06-28T18:06:35Z